Annals of Hematology

, Volume 97, Issue 5, pp 905–907 | Cite as

Combined PD-1 and JAK1/2 inhibition in refractory primary mediastinal B-cell lymphoma

  • Marcel Nijland
  • Tom van Meerten
  • Annika Seitz
  • Gerwin Huls
  • Robby Kibbelaar
  • Lydia Visser
  • Anke van den Berg
  • Arjan Diepstra
Letter to the Editor



hematopoietic cell transplantation


Janus kinase 2


Janus kinase-signal transducer and activator of transcription


programmed cell-death ligand ½


primary mediastinal B-cell lymphoma


Availability of data and material

All data generated or analyzed are in the current report.

Authors’ contributions

MN designed the paper. MN, TM, and GH treated the patient. AD and RK provided pathological review. AS, LV, and AB performed FISH analysis. All authors contributed in writing the manuscript. All authors read and approved the final manuscript.

Compliance with ethical standards

Ethics approval and consent to participate

The patient provided informed consent for all her sequential therapies.

Consent for publication

Written informed consent was obtained from the patient for the publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Conflict of interests

The authors declare that they have no conflict interests.

Supplementary material

277_2018_3233_MOESM1_ESM.docx (24 kb)
ESM 1 (DOCX 23 kb)


  1. 1.
    Gaulard P, Harris NL, Pileri SA. (2017) Primary mediastinal (thymic) large B-cell lymphoma. In Swerdlow SH, Camp E, Harris NL, et al WHO classification of tumours of haematopoeitic and lymphoid tissues Revised 4th ed International Agency for Research on Cancer:314–316Google Scholar
  2. 2.
    Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, de Leval L, Kurtin P, Dal Cin P, Ladd C, Feuerhake F, Aguiar RC, Li S, Salles G, Berger F, Jing W, Pinkus GS, Habermann T, Dalla-Favera R, Harris NL, Aster JC, Golub TR, Shipp MA (2003) The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102(12):3871–3879. CrossRefPubMedGoogle Scholar
  3. 3.
    Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, Chapuy B, Takeyama K, Neuberg D, Golub TR, Kutok JL, Shipp MA (2010) Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116(17):3268–3277. CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Steidl C, Gascoyne RD (2011) The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood 118(10):2659–2669. CrossRefPubMedGoogle Scholar
  5. 5.
    Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, Steinberg SM, Grant C, Wright G, Varma G, Staudt LM, Jaffe ES, Wilson WH (2013) Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 368(15):1408–1416. CrossRefPubMedCentralPubMedGoogle Scholar
  6. 6.
    Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance, Australasian Leukaemia and Lymphoma Group., Eastern Cooperative Oncology Group., European Mantle Cell Lymphoma Consortium., Italian Lymphoma Foundation., European Organisation for Research., Treatment of Cancer/Dutch Hemato-Oncology Group., Grupo Español de Médula Ósea., German High-Grade Lymphoma Study Group., German Hodgkin's Study Group., Japanese Lymphorra Study Group., Lymphoma Study Association., NCIC Clinical Trials Group., Nordic Lymphoma Study Group., Southwest Oncology Group., United Kingdom National Cancer Research Institute (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059–3068. CrossRefPubMedCentralPubMedGoogle Scholar
  7. 7.
    Zinzani PL, Pellegrini C, Chiappella A, di Rocco A, Salvi F, Cabras MG, Argnani L, Stefoni V (2017) Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. Blood 129(16):2328–2330. CrossRefPubMedGoogle Scholar
  8. 8.
    Kim JS, Kang HJ, Dong S et al (2016) The efficacy of JAK2 inhibitor in heavily pretreated classical Hodgkin lymphoma: a prospective pilot study of ruxolitinib in relapsed or refractory classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 128:1820Google Scholar
  9. 9.
    Zinzani PL, Ribrag V, Moskiwitz CH et al (2017) Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood 130(3):267–270. CrossRefPubMedGoogle Scholar
  10. 10.
    Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na IK, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lübbert M, Wäsch R, Scheid C, Stölzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Gräff A, van der Velden W, Huls G, Mielke S, Grigoleit GU, Kuball J, Flynn R, Ihorst G, Du J, Blazar BR, Arnold R, Kröger N, Passweg J, Halter J, Socié G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N (2015) Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 29(10):2062–2068. CrossRefPubMedCentralPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of HematologyUniversity of Groningen, University Medical Centre GroningenGroningenthe Netherlands
  2. 2.Department of Pathology and Medical BiologyUniversity of Groningen, University Medical Centre GroningenGroningenthe Netherlands
  3. 3.Department of PathologyPathology FrieslandLeeuwardenthe Netherlands

Personalised recommendations